Meeting
2021 ASCO Annual Meeting
A prospective phase I/IIa trial to evaluate the safety and efficacy of GTA002, an off-the-shelf, ex vivo-cultured allogeneic NK cell preparation in patients with acute myeloid leukemia in complete morphological remission who have measurable residual disease.
Authors
Michael Heuser
Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
Michael Heuser , Walter M. Fiedler , Tessa Kerre , Johan Maertens , Jakob Passweg , Arjan Van De Loosdrecht , Antonia Maria Mueller , Jean-Henri Bourhis , Katarzyna Nowek , Jan Spanholtz , Virginie Bonnamain , Stephan Winckels , Arnold Ganser
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
EudraCT number 2019-003686-17
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS7053)
DOI
10.1200/JCO.2021.39.15_suppl.TPS7053
Abstract #
TPS7053
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Examining safety and durable disease remission in R/R B-ALL after autologous CD19-directed CAR T cells produced by novel PRIMCAR manufacture platform.
First Author: Zhi Yang
Poster
2023 ASCO Annual Meeting
Safety and efficacy profile of a very low dose of MC-1-50 for treatment of r/r NHL.
First Author: Shiqi Li
Poster
2021 ASCO Annual Meeting
A phase 1 dose escalation and cohort expansion study of the safety and efficacy of allogeneic CRISPR-Cas9–engineered T cells (CTX110) in patients (Pts) with relapsed or refractory (R/R) B-cell malignancies (CARBON).
First Author: Joseph McGuirk
Poster
2019 ASCO Annual Meeting
ZUMA-8: A phase 1/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
First Author: Ian Flinn